Teachers Retirement System of The State of Kentucky Has $8.75 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Teachers Retirement System of The State of Kentucky reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,644 shares of the medical research company's stock after selling 1,879 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.10% of Bio-Rad Laboratories worth $8,753,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Venturi Wealth Management LLC raised its holdings in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares in the last quarter. GeoWealth Management LLC boosted its stake in shares of Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after acquiring an additional 72 shares in the last quarter. Picton Mahoney Asset Management grew its holdings in shares of Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after acquiring an additional 35 shares during the last quarter. Asset Planning Inc acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth $33,000. Finally, UMB Bank n.a. increased its stake in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BIO has been the topic of a number of research reports. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $380.20.

Bio-Rad Laboratories Price Performance

BIO stock traded up $0.90 during trading on Thursday, hitting $249.75. 222,602 shares of the stock traded hands, compared to its average volume of 316,419. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The stock has a market cap of $7.00 billion, a price-to-earnings ratio of -3.84 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a one year low of $215.38 and a one year high of $387.99. The company has a 50 day simple moving average of $251.85 and a 200 day simple moving average of $309.16.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.